Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention

This study tests whether giving an SGLT-2 inhibitor (a type of diabetes and heart medication) around the time of a heart procedure can reduce heart muscle damage and prevent the heart from enlarging after a heart attack. Participants receive a stent procedure to open blocked arteries. **You may be eligible if...** - You are 18 or older and have been diagnosed with a heart attack (STEMI or NSTEMI) - Your heart pumping function is less than 50%, or you have signs of fluid buildup in the lungs - You are scheduled for a procedure to open a blocked artery (PCI/stent) **You may NOT be eligible if...** - The blocked artery is not suitable for a stent - You needed emergency heart resuscitation before the procedure - You have had a previous heart attack or previous heart failure - You are already taking an SGLT-2 inhibitor (such as empagliflozin, dapagliflozin, or canagliflozin) - You have type 1 diabetes or active infection - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.